Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2901)	6/11/2010 10:24:09 AM
From: Jibacoa	Respond to of 3722

IDIX is up for 2nd day on a roll.<g> Volume is low < 0.25 its ADV bigcharts.marketwatch.com IDIX announced yesterday that it has initiated a 3-day proof-of-concept study of IDX320, its protease inhibitor for the treatment of hepatitis C. It they have favorable results from the IDX320 proof-of-concept study, they plan to discuss with the FDA a direct-acting antiviral combination strategy with IDX320 and IDX184. <g> The proof-of-concept trial in HCV-infected patients is a PI/II evaluating the safety and antiviral activity of IDX320 in treatment-naive adult patients infected with chronic hepatitis C. IDIX is still trading below the resistance of its Apr Hs. bigcharts.marketwatch.com Revenues on the 4thQ & 1st Q were lower, but it was able to cut some the loss on the 1stQ.< g> The ACTAY is $6.75 The stock is trying to get off its longer term DT. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2901)	7/1/2010 3:53:47 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AVNR is trading near its intraday H,it was up 14% and is still up 12.45% on volume of > 6M >2x its ADV bigcharts.marketwatch.com An annalyst at Jeffries recommended the stock with a "buy" rating, saying that is likely that the FDA will approve the NDA for Zenvia. The FDA is expected to make a decision on the drug in October.<g> The stock has resistance fro its June 10 H of $2.90 before it can test the more important above the $3 level. The ACTAY is $7.98 I will still keep a TT at $4 <g> bigcharts.marketwatch.com Bernard